MP0730

Molecular Partners plans to eliminate up to 55 positions, or roughly 44% of its workforce, as it reshapes itself around targeted radiotherapy and its lead Radio-DARPin candidate MP0712. The strategic concentration could extend resources around a promising platform, but the company is making that organisational commitment before efficacy data from MP0712 are expected in 2027.